"
Phase I Dose Escalation Study with the Lewis Y Carbohydrate Specific Humanized Antibody IGN311"
written by Daniel Oruzio, Günter Waxenecker, Christoph Aulmann, Bruno Märkl, Theodor Wagner, Geert Mudde, Manfred Schuster, Norbert Eller, Andrea Mayer, Stefan Stranner, Gottfried Himmler, Hans Loibner, Günter Schlimok, Ralf Kircheis, Andreas Nechansky,
published by
Journal of Cancer Therapy,
Vol.2 No.5, 2011
has been cited by the following article(s):
[1]
|
Application of Lectin Array Technology for Biobetter Characterization: Its Correlation with FcγRIII Binding and ADCC
Microarrays,
2016
DOI:10.3390/microarrays6010001
|
|
|
[2]
|
Safety and Therapeutic Efficacy of the Lewis Y Carbohydrate Specific Humanized Antibody MB311 in Patients with Malignant Effusion
Journal of Cancer Therapy,
2014
DOI:10.4236/jct.2014.51004
|
|
|
[3]
|
Induction of Human Anti-Human Antibody Responses (Ab2) after Application of a Humanized Lewis Y Carbohydrate Specific Antibody (Ab1): Connection of Prolonged Disease Stabilization with Ab3 Induction?
Journal of Cancer Therapy,
2012
DOI:10.4236/jct.2012.34038
|
|
|